Multiple downstream fibrotic and immune processes

The term "Multiple downstream fibrotic and immune processes" refers to the integrated network of cellular activities and signaling pathways that drive tissue remodeling and chronic inflammation. It is not a single therapeutic target, such as a specific receptor or enzyme, but rather a collective description of the pathological outcomes resulting from various activated signaling pathways (Wynn TA, J Pathol 2008;214(2):199-210). These processes are typically initiated by upstream mediators like Transforming Growth Factor-beta (TGF-β) and receptor tyrosine kinases (RTKs), which trigger fibroblast activation, myofibroblast differentiation, and the excessive deposition of extracellular matrix (Henderson NC, et al., Nature 2020;587(7835):555-566). In clinical pharmacology, this phrase is frequently used to describe the pleiotropic effects of multi-target inhibitors, such as nintedanib, which disrupt these integrated cascades to treat fibrotic lung diseases (Richeldi L, et al., N Engl J Med 2014;370(22):2071-2082). Because these processes involve a coordinated response between immune cells and structural tissues, they represent a broad functional category rather than a discrete molecular entity (Wollin L, et al., J Pharmacol Exp Ther 2014;349(2):209-220). Consequently, while the term is useful for describing a drug's overall impact on disease pathology, it does not identify a specific protein or gene target (Distler O, et al., N Engl J Med 2019;380(26):2518-2528).

Other names

Fibrotic signaling cascadesDownstream fibrotic pathwaysIntegrated fibrotic and immune responses

Inhibition of upstream signaling molecules (e.g., receptor tyrosine kinases or TGF-beta) to modulate downstream fibrotic and inflammatory cascades.